This 6-week trial will study the effectiveness of 5 different doses of the Pfizer drug Lyrica® (generic name pregabalin) versus a placebo (fake) dose. In all, 26 trial centers in the U.S., Austria, Germany, and Spain are actively recruiting.
Inclusion criteria for the trial include moderate to severe idiopathic restless legs syndrome, ages 18 to 65, with symptoms occurring predominantly in the evening that interfere with sleep onset or maintenance. The study will measure relative ability of different pregabalin doses taken 1 to 3 hours before bedtime to improve overall symptom severity and sleep quality.
For more detail and to review the locations of the 26 study centers, obtain contact information for a center near you, or call the Pfizer call center for more information, visit the ClinicalTrials.gov listing for this study – “Lyrica Dose Response Study With Restless Legs Syndrome (RLS) Patients”
(http://www.clinicaltrials.gov/ct2/show/NCT00676403) and mention ClinicalTrials ID NCT00676403